At the forefront of the SBF 120, bioMérieux shares gain 3.5% despite Morgan Stanley

A rebound that places the share above its three moving averages

The bioMérieux share gains 3.54% to €83.25, while the SBF 120 advances by 0.92%. The movement places it among the strongest gainers in the index. It brings gains to nearly 8% over a week and more than 15% over a month, following the commercial launch of Spinchip at the end of September.

The price has thus risen 12% above the 50-day moving average, at €74.31, and only 0.79% above the 200-day moving average, at €82.60. With an RSI at 67, the increase remains below the overbought zone. Over one year, the share remains down 25.87%.

Morgan Stanley raises its target to €71 but remains underweight

In the detail of analyst opinions, Morgan Stanley raised its price target from €66 to €71 today, while maintaining its underweight opinion. This target is nearly 15% below the current price. On fundamentals, the group confirmed on August 4, with its first half 2026 results, organic revenue growth of 3% to 5% and CEBIT growth of 0% to 10% for the fiscal year.

It cited among its risks a 17% decline in BIOFIRE respiratory panels. The €95.40 zone, which acts as resistance, remains the next bullish reference point for the price.